Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9UBL9

UPID:
P2RX2_HUMAN

ALTERNATIVE NAMES:
ATP receptor; Purinergic receptor

ALTERNATIVE UPACC:
Q9UBL9; A6NGB4; A6NH93; A6NHC2; A6NHU3; A6NIG9; Q6V9R6; Q9NR37; Q9NR38; Q9UHD5; Q9UHD6; Q9UHD7; Q9Y637; Q9Y638

BACKGROUND:
The P2X purinoceptor 2, known alternatively as ATP receptor or Purinergic receptor, is integral to cellular mechanisms like synaptic transmission, neuromuscular coordination, and sensory perception. It governs ion channel activities triggered by extracellular ATP, facilitating crucial processes in sensory neurons, muscle formation, and the auditory system.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in Deafness, autosomal dominant, 41, marked by severe sensorineural hearing loss, P2X purinoceptor 2 represents a promising target for therapeutic intervention. Exploring this protein's role could unveil new pathways for treating hearing impairments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.